S100A9 and acute myeloid leukemia: To evaluate whether S100A9 targeting had a therapeutic effect on AML resistant cell lines, we tested the anti-leukemic effect of S100A9-siRNA and tasquinimod on venetoclax-insensitive cell lines THP-1 and OCI-AML3.